Agenus Inc. Cost of Revenue

Cost of Revenue of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending June 29, 2020 was $634 Thousand (a 9506.06% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 258.8%
  • Annual Cost of Revenue for 2013 was $536 Thousand (a -20.22% decrease from previous year)
  • Annual Cost of Revenue for 2012 was $672 Thousand (a 446.79% increase from previous year)
  • Twelve month Cost of Revenue ending June 29, 2020 was $897 Thousand (a 67.36% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue decreased by -7.42% year-over-year
Trailing Cost of Revenue for the last four month:
29 Jun '20 30 Dec '13 29 Sep '13 29 Jun '13
$897 Thousand $536 Thousand $832 Thousand $969 Thousand
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Agenus Inc.

Most recent Cost of Revenueof AGEN including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Agenus Inc.

Agenus Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.63
2013 $0.01 $0.08 $0.18 $0.27 $0.54
2012 $0.3 $0.22 $0.13 $0.02 $0.67
2010 $0.07 $0.06 $0.12

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.